Merck
CN

Y0000602

甲氨蝶呤

European Pharmacopoeia (EP) Reference Standard

登录to View Organizational & Contract Pricing

Select a Size

Change View
别名:
(+)-氨甲蝶呤, 4-氨基-N10-甲基巯基-L-谷氨酸, MTX, 氟安定, 氨甲叶酸, 氨甲喋呤
Empirical Formula (Hill Notation):
C20H22N8O5
CAS号:
分子量:
454.44
Beilstein:
70669
MDL编号:
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API family

methotrexate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Gene Information

human ... DHFR(1719)

正在寻找类似产品? Visit 产品对比指南

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
M1000000PHR1396Y0001668
Methotrexate for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000602

甲氨蝶呤

Methotrexate European Pharmacopoeia (EP) Reference Standard

M1000000

甲氨蝶呤

Methotrexate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1396

甲氨蝶呤

Methotrexate for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001668

甲氨蝶呤

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

-

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

methotrexate

API family

methotrexate

API family

methotrexate

API family

methotrexate

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Methotrexate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Eye Irrit. 2 - Muta. 2 - Repr. 1B - Skin Irrit. 2

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

其他客户在看

Slide 1 of 3

1 of 3

Methotrexate hydrate powder, BioReagent, suitable for cell culture, ≥98% (HPLC)

Sigma-Aldrich

M8407

甲氨蝶呤 水合物

Methotrexate hydrate ≥99.0% (sum of enantiomers, HPLC)

Sigma-Aldrich

06563

甲氨蝶呤 水合物

Methotrexate hydrate ≥98% (HPLC), powder

Sigma-Aldrich

A6770

甲氨蝶呤 水合物

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
Kalle Jyri Aaltonen et al.
The Journal of rheumatology, 42(3), 372-378 (2015-01-17)
Because of the role of tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk of malignancies and infections. The objective of our study was to assess the incidence of serious
Giovanni L Mancardi et al.
Neurology, 84(10), 981-988 (2015-02-13)
To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. We conducted a multicenter, phase II, randomized trial including patients with secondary

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门